New Market - April 2, 2020
LINK Medical Research opens London office
LINK Medical has announced the opening of its new UK office at MedCity, in London’s City region. The expansion to London will enable the company to bring significant value to UK-based biopharma and medtech companies by accelerating their product development, they state in their press release. The MedCity location was strategically chosen for its world-leading […]
New Market - March 30, 2020
AstraZeneca’s Imfinzi approved in the US for extensive small cell lung cancer
AstraZeneca’s Imfinzi has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care (SoC) chemotherapies, etoposide plus either carboplatin or cisplatin (platinum-etoposide). The approval by the Food and Drug Administration was based on positive results from the Phase III CASPIAN trial showing […]
New Market - February 10, 2020
Nanoform establishes US subsidiary
Nanoform has established Nanoform USA Inc., a wholly owned subsidiary in the US. This is a natural progression for the company as it continues to increase the impact of its nanonization technology and expand its major pharma client base in the US, it states. A new Head of US sales The establishment of Nanoform USA […]
New Market - February 4, 2020
Oasmia launches its ovarian cancer treatment drug in Sweden, Denmark and Finland
Oasmia Pharmaceutical is launching its product, Apealea 60 mg, an ovarian cancer treatment drug, in Sweden, Denmark and Finland. The first batch of the drug has been shipped to distributors in these countries, states the company. Transition towards becoming a fully integrated pharmaceutical company Apealea is a patented, water-soluble, intravenously injectable formulation of paclitaxel, developed […]
New Market - January 23, 2020
LIDDS’s Nanozolid registered in the US
LIDDS has announced that the United States Patent and Trademark Office has registered the trademark NanoZolid. LIDDS thereby has exclusive rights to the trademark for products and services in the USA and in the EU, where NanoZolid has been registered since 2016. “This is an essential, although expected, step in establishing the concept of LIDDS […]
Financing - January 9, 2020
Combinostics raises €3.9 million
Finnish Combinostics has announced the closure of a €3.9 million series A funding round that will see the company scale its platform for early-stage Alzheimer’s diagnosis to the US and Asia. The round was jointly-led by Industrifonden and NordicNinja VC, with Combinostics representing NordicNinja’s fifth deep tech investment over the past 6 months. “I would […]
